시장보고서
상품코드
1619189

피임약 시장 규모, 점유율, 성장 분석 : 유형별, 유통경로별, 지역별 - 산업 예측(2024-2031년)

Contraceptive Drugs Market Size, Share, Growth Analysis, By Type (Oral Contraceptives, Combined Oral Contraceptive Pills), By Distribution (Hospital & Clinics, Retail Pharmacy), By Region - Industry Forecast 2024-2031

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 242 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 피임약 시장 규모는 2022년에 195억 달러로 평가되며, 2023년 210억 8,000만 달러에서 2031년에는 393억 1,000만 달러로 성장하며, 예측 기간 중(2024-2031년) CAGR은 8.1%로 성장할 전망입니다.

피임약과 디바이스 시장은 성감염증의 이환율 상승과 피임법을 사용할 수 없는 여성 증가로 인해 성장할 것으로 예상되고 있습니다. 세계보건기구(WHO)가 강조한 바와 같이, 2019년에는 11억 명 이상의 가임기 여성이 가족계획이 필요하며, 2억 7,000만 명이 충족되지 않은 수요를 경험하고 있습니다. 표적화된 프로그램과 인식 개선을 통해 계획되지 않은 임신에 대처하기 위한 노력은 시장 확대의 원동력이 될 것으로 예상됩니다. 반면, 피임약의 부작용, 불임률 증가에 대한 우려, 선진국의 성교육 불일치 등의 문제는 성장을 저해하는 요인으로 작용할 수 있습니다. 이러한 역학은 피임약 시장에서 접근성과 사용자 만족도를 높이기 위한 혁신적인 솔루션의 필요성을 강조하고 있습니다.

목차

서론

  • 분석 목적
  • 시장 범위
  • 정의

분석 방법

  • 정보 조달
  • 2차·1차 데이터 방법
  • 시장 규모 예측
  • 시장의 상정과 제약

개요

  • 시장의 개요와 전망
  • 수급 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

시장의 주요 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2023년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

세계의 피임약 시장 규모·CAGR : 유형별(2024-2031년)

  • 시장 개요
  • 경구 피임약
  • 복합 경구 피임약
  • 프로게스토겐 전용 정제
  • 국소 피임약
  • 피임 주사제
  • 기타

세계의 피임약 시장 규모·CAGR : 유통경로별(2024-2031년)

  • 시장 개요
  • 병원·클리닉
  • 소매 약국
  • 온라인 약국
  • 기타

세계의 피임약 시장 규모·CAGR(2024-2031년)

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2023년)
  • 주요 기업이 채택한 전략
  • 시장의 최근 동향
  • 주요 기업의 시장 점유율(2023년)
  • 주요 기업의 개요
    • 기업 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출의 전년대비 비교(2021-2023년)

주요 기업 개요

  • Pfizer Inc.(미국)
  • Bayer AG(독일)
  • Teva Pharmaceutical Industries Ltd.(이스라엘)
  • Mylan N.V.(네덜란드)
  • Novartis AG(스위스)
  • Johnson & Johnson(미국)
  • GlaxoSmithKline plc(UK)
  • Allergan plc(아일랜드)
  • Agile Therapeutics, Inc.(미국)
  • Piramal Healthcare(인도)
  • Organon & Co.(네덜란드)
  • HRA Pharma(프랑스)
  • CooperSurgical, Inc.(미국)
  • Church & Dwight Co., Inc.(미국)
  • Merck & Co., Inc.(미국)
  • Famy Care Ltd.(인도)
  • Sinopharm Group Co., Ltd.(중국)
  • Sun Pharmaceutical Industries Ltd.(인도)
  • Torrent Pharmaceuticals Ltd.(인도)
  • Dr. Reddy's Laboratories Ltd.(인도)

결론과 권장사항

KSA 25.01.13

Global Contraceptive Drugs Market size was valued at USD 19.5 billion in 2022 and is poised to grow from USD 21.08 billion in 2023 to USD 39.31 billion by 2031, growing at a CAGR of 8.1% during the forecast period (2024-2031).

The market for contraceptive drugs and devices is poised for growth due to the rising incidence of sexually transmitted diseases and an increasing number of women lacking access to these options. As highlighted by the World Health Organization, in 2019, more than 1.1 billion women of reproductive age were in need of family planning, with 270 million experiencing unfulfilled demand. Efforts to address unplanned pregnancies through targeted programs and heightened awareness are expected to drive market expansion. Conversely, challenges such as side effects associated with contraceptives, concerns over growing infertility rates, and inconsistencies in sex education in developed nations may impede growth. These dynamics underscore the need for innovative solutions to enhance accessibility and user satisfaction in the contraceptive market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contraceptive Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contraceptive Drugs Market Segmental Analysis

Global Contraceptive Drugs Market is segmented by type, distribution and region. Based on type, the market is segmented into oral contraceptives, combined oral contraceptive pills, progestogen-only pills, topical contraceptives, contraceptive injectable and others. Based on distribution, the market is segmented into hospital & clinics, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contraceptive Drugs Market

The Global Contraceptive Drugs market is significantly driven by the need to prevent unwanted pregnancies, particularly among poor and low-income populations where the incidence of unintended pregnancy remains high. A key factor behind this issue is the reliance on traditional contraception methods, which are often less effective. This situation is further compounded by the prevalence of unsafe abortions and associated maternal mortality rates. For instance, in Latin America, adolescents under 16 face a fourfold increase in the risk of maternal death compared to women in their thirties. Consequently, the adoption of contraceptive drugs plays a vital role in reducing the rates of unplanned pregnancies, thereby improving maternal health outcomes.

Restraints in the Global Contraceptive Drugs Market

The global contraceptive drugs market is facing significant constraints due to the adverse effects associated with birth control pills. Prolonged use, defined as ten years or more, can lead to various side effects including headaches, nausea, and abnormal bleeding. Additionally, medications that contain estrogen and progesterone have been linked to an elevated risk of developing blood clots, which can result in serious complications such as heart attacks. These potential health risks contribute to consumer hesitancy and reduce market demand, ultimately impeding the growth of the contraceptive drugs sector worldwide. Addressing these concerns is crucial for market expansion.

Market Trends of the Global Contraceptive Drugs Market

The Global Contraceptive Drugs market is experiencing a significant shift towards innovative technological advancements, particularly in the realm of digital contraception. This trend encompasses a growing emphasis on period tracking applications that empower users to monitor their menstrual cycles and assess pregnancy risk. A notable example is Berlin-based Clu's all-digital contraceptive, Clu Birth Control, which leverages comprehensive period data and predictive algorithms to enhance contraceptive efficiency. The ability for users to adjust their sexual behaviors based on personalized risk analytics positions digital contraception as a game-changer in reproductive health, reflecting a broader consumer demand for tailored, tech-driven contraceptive solutions.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2023
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Contraceptive Drugs Market Size by Type & CAGR (2024-2031)

  • Market Overview
  • Oral Contraceptives
  • Combined Oral Contraceptive Pills
  • Progestogen-Only Pills
  • Topical Contraceptives
  • Contraceptive Injectable
  • Others

Global Contraceptive Drugs Market Size by Distribution & CAGR (2024-2031)

  • Market Overview
  • Hospital & Clinics
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Contraceptive Drugs Market Size & CAGR (2024-2031)

  • North America (Type, Distribution)
    • USA
    • Canada
  • Europe (Type, Distribution)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Distribution)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Distribution)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Distribution)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2023
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agile Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Piramal Healthcare (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Organon & Co. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HRA Pharma (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CooperSurgical, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Church & Dwight Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Famy Care Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sinopharm Group Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Torrent Pharmaceuticals Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제